版本:
中国

BRIEF-Novartis presents long-term data on Gilenya

Sept 16 Novartis says:

* Says data presented at ECTRIMS show benefit of Gilenya on patient disability progression at 10 years

* Says Fewer Patients Who Stayed On Gilenya Therapy For 8 10 years developed secondary progressive ms compared to those who discontinued it

* Says study shows that patients with relapsing remitting multiple sclerosis (rrms) continuously treated with gilenya() (fingolimod) had significantly lower disability progression compared to those whose treatment was interrupted Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

更多 瑞士市场报道

热门文章

编辑推荐

文章推荐